trial · primary record
Sacituzumab Govitecan
Gland
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 63 |
| Primary completion | 2028-07-31 |
| Primary endpoint | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
| Registry ID | NCT05884320 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:54.800Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05884320
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.